Daniel Loeb
Third Point
Daniel Loeb 10X Genomics Inc stake
total: 588
Third Point TXG trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2020 Q3
- Held for:
- 1 quarter
- Latest activity:
- 2020 Q4
According to 2026 Q2 report, Daniel Loeb doesn't hold any 10X Genomics Inc (TXG) shares. To date, the estimated cost basis is nearly $124.68 for "buy" trades and estimated average "sell" price is $124.68. Third Point first purchased TXG in 2020 Q3, initially acquiring 123,268 shares. Since the initial investment in 10X Genomics Inc (TXG), Third Point has made 1 more transaction.
When did Daniel Loeb sell 10X Genomics Inc (TXG)?
Daniel Loeb sold off the entire 10X Genomics Inc (TXG) position in 2020 Q4.
When did Daniel Loeb buy 10X Genomics Inc (TXG)?
Daniel Loeb first invested in 10X Genomics Inc (TXG) in 2020 Q3 at the reported quarter-end price of $124.68 per share.
What's the cost basis of Third Point's TXG stake?
The estimated cost basis for 10X Genomics Inc (TXG) stake is around $124.68 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $124.68
- Weighted AVG sell price:
- $124.68
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.